OtoSim Night revolutionizes how students learn to identify ear pathologies
On Feb. 13, 2013, almost 100 second-year University of Toronto (U of T) medical students participated in an optional, intensive, one-hour otoscopy workshop using the OtoSim™ — a training and simulation system that is radically changing the way students in Canada and around the world learn this poorly-acquired medical skill.
And, if you want to use simulation technology to change the way medical professionals are taught, ear disease is a good place to ...
Dr. Hossein Rahnama is one of three new members of the Natural Sciences and Engineering Research Council of Canada. The Honourable Christian Paradis, Minister of Industry, announced the appointments on Feb. 22, 2013.
Rahnama is founder and CEO of Flybits Inc., Research and Innovation director at Ryerson University's Digital Media Zone, co-founder of Ryerson's Ubiquitous and Pervasive Computing Lab.
Rahnama is currently in Barcelona to launch Flybits LITE at Mobile World Congress 2013.
In 2012, he was named to MIT Technology Review‘s prestigious 35 ...
Flybits' Context-Aware and Intelligent Mobility Solutions on exhibit Feb. 25 to 28, Canadian Pavilion, Stand 7F50, Booth 14
TORONTO, Canada (Feb. 14, 2013) – Flybits, a start-up company that develops context-aware and intelligent mobility solutions, today announced that they will be exhibiting at Mobile World Congress 2013 to launch a revolutionary mobile product called Flybits LITE.
Flybits LITE, an innovative Platform as a Service (PaaS), enables the quick creation and deployment of context-aware mobile computing applications for enterprises without the dependency of dedicated ...
TORONTO, ON (Feb. 19, 2013) – XLV Diagnostics Inc., a start-up company working to commercialize a faster, cheaper and better digital mammography technology, has received a $500,000 investment from FedNor.
Over 600 million women living in developing countries have inadequate access to breast screening for early cancer detection. In the developed world, many radiology departments are replacing traditional film and screen systems with digital technologies. In both cases, better digital mammography technology promises to solve logistical challenges and save money.
XLV’s solution has ...
February 19, 2013
in Funding or Fundraising-Announcements, Government Partners, Member Institutions, News, Partnerships, Portfolio, Start-Up Companies, Sunnybrook Health Sciences Centre, The Ontario Institute for Cancer Research (OICR), Thunder Bay Regional Research Institute (TBRRI), XLV Diagnostics Inc.
TORONTO, Feb. 19, 2013 — Xagenic Inc., a privately-held molecular diagnostics company, today announced that it will receive up to $990,000 in funding from the Government of Canada to support design and development of the first lab-free molecular diagnostic platform with a 20-minute time to result.
The Honourable Gary Goodyear, Minister of State for the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), made the announcement in the keynote speech at the Conference Board of Canada's Business Innovation Summit 2013 ...
India's Kumbh Mela, an annual mass Hindu pilgrimage of faith, is unlikely to create a disease outbreak that spreads beyond the country's borders, Dr. Kamran Khan, founder of BioDiaspora, tells Maclean's Magazine's Hannah Hoag in "As millions gather for Kumbh Mela, doctors are watching" (February 11, 2013).
Here's an excerpt (emphasis ours):
Unlike the hajj or the Olympics, the Kumbh Mela is primarily a domestic event. While flights into Saudi Arabia spike to five times normal during the hajj, “with the Kumbh Mela, ...
Networks of Centres of Excellence recognizes strength of partnership between MI and its 16 member institutions
TORONTO, February 5, 2013 — How do you make sure the brilliant ideas emerging from Toronto’s academic research community get the best possible chance to succeed?
MaRS Innovation (MI), created in 2008, bridges the chasm between these early-stage technologies and successful start-up companies and licensable technologies. By offering early-stage funding in tandem with hands-on management, mentorship and IP strategy protection, MI acts as a commercialization agent for ...
February 6, 2013
in Awards, Baycrest Centre for Geriatric Care, Centre for Addiction and Mental Health (CAMH), Funding or Fundraising-Announcements, Government Partners, Holland Bloorview Kids Rehabilitation Hospital, Industry Partners, Licenseable Technologies, MaRS Discovery District, Member Institutions, News, Partnerships, Portfolio, Ryerson University, Sinai Health, St. Michael's Hospital, Start-Up Companies, Sunnybrook Health Sciences Centre, The Hospital for Sick Children (SickKids), The Ontario Institute for Cancer Research (OICR), Thunder Bay Regional Research Institute (TBRRI), TIAP Staff, University Health Network, University of Toronto, Women's College Hospital, York University
Dr. Raphael Hofstein, president and CEO of MaRS Innovation, delivered a guest lecture on February 1,2013 at the Revitalizing Medical BioTechnology Commercialization symposium, hosted by Stanford University's NIH Graduate Training Program in Biotechnology.
The one-day event brought academic, venture capital and industry thought leaders together to reflect on the challenges facing technology transfer processes across the biotech industry. (more…)
"There is a path somewhere between extended study and becoming an office worker," wrote The Varsity's Angela Brock, in "Be Your Own Boss: Student entrepreneurs combine creativity and business to forge new career paths" (February 3, 2012). "As it turns out, there are plenty of opportunities for those looking to flex their entrepreneurial muscles without straying too far from the bosom of U of T."
Brock's article describes UTEST, the joint U of T-MaRS Innovation program that helps students, faculty and recent ...
Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. This post coincided with World Cancer Day.
What if you could use a cancer tumour’s proteomic profile to make it easier to target and destroy?
Targeting specific proteins on the surface of individual tumours—or, more precisely, targeting a cell receptor that naturally allows substances to pass into a cell—would allow clinicians to more effectively deliver ...